Status | Study |
Active, not recruiting |
Study Name: Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Condition: Fallopian Tube Carcinosarcoma Fallopian Tube Clear Cell Adenocarcinoma Date: 2009-10-02 Interventions: Biological: Bevacizumab Given |
Active, not recruiting |
Study Name: Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Condition: Malignant Ovarian Mixed Epithelial Tumor Ovarian Brenner Tumor Date: 2009-08-01 Interventions: Biological: Bevacizumab Given |
Completed |
Study Name: A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Condition: Fallopian Tube Carcinoma Malignant Ovarian Mixed Epithelial Tumor Date: 2009-07-14 Interventions: Biological: Urokinase-Derived Peptide A6 |
Completed |
Study Name: Collecting Tumor Samples From Patients With Gynecological Tumors Condition: Borderline Ovarian Clear Cell Tumor Borderline Ovarian Serous Tumor Date: 2009-05-09 Interventions: Other: Laboratory Biomarker Analysis Correlative studies |
Active, not recruiting |
Study Name: Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Condition: Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Date: 2009-04-24 Interventions: Drug: Elesclomol Sodium Given |
Completed |
Study Name: Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Condition: Chemotherapeutic Agent Toxicity Endometrial Adenocarcinoma Date: 2008-12-20 Interventions: Drug: Paclitaxel Given IV or i |
Recruiting |
Study Name: Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Condition: Clear Cell Adenocarcinoma Fallopian Tube Clear Cell Adenocarcinoma Date: 2007-11-29 Interventions: Biological: Bevacizumab Given |
Completed |
Study Name: Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Condition: Brenner Tumor Fallopian Tube Cancer Date: 2007-04-25 Interventions: Biological: sargramostim Given |
Completed |
Study Name: Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Condition: Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Date: 2005-12-06 Interventions: Biological: Bevacizumab Given |
Active, not recruiting |
Study Name: Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Condition: Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Date: 2005-04-18 Interventions: Other: Clinical Observation Un |